跳至主要内容
临床试验/CTIS2023-503734-47-00
CTIS2023-503734-47-00进行中(未招募)1 期

AZP-3813-CLI-001

Amolyt Pharma0 个研究点目标入组 101 人开始时间: 2023年3月20日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Amolyt Pharma
入组人数
101

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Amolyt Pharma

相似试验

招募中
1 期
A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).Acute myeloid leukemia or myelodysplastic syndrome of high risk group,that has come back after treatment or cannot be cured or treated by anyother known therapies.MedDRA version: 21.0Level: LLTClassification code: 10060558Term: Acute myeloid leukemia recurrent Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10081514Term: Acute myeloid leukemia refractory Class: 10029104
CTIS2023-503869-34-00Celgene Corp.180
进行中(未招募)
1 期
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.Asthma
CTIS2024-514247-28-00Chiesi Farmaceutici S.p.A.90
进行中(未招募)
1 期
A Study of ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer.
CTIS2023-504514-29-00Astellas Pharma Global Development Inc.240
进行中(未招募)
1 期
A trial to investigate the effect of acalabrutinib on skin prick test wheal size in adults with grass pollen allergy
CTIS2023-505783-11-00Alk-Abello A/S12
进行中(未招募)
1 期
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroidsTest of vasocontriction properties for classification of topical steroid potencyMedDRA version: 20.0Level: LLTClassification code: 10047140Term: Vasoconstriction peripheral Class: 10047065
CTIS2023-507241-28-00Cassiopea S.p.A.33